Disease Domain | Count |
---|---|
Infectious Diseases | 3 |
Immune System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 2 |
Prophylactic vaccine | 1 |
Chemical drugs | 1 |
Top 5 Target | Count |
---|---|
TLR4(Toll like receptor 4) | 1 |
TLR(Toll-like receptor) | 1 |
Target |
Mechanism TLR4 agonists |
Active Org. Inimmune Corp.Startup |
Originator Org. Inimmune Corp.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TLR agonists |
Active Org. Inimmune Corp.Startup |
Originator Org. Inimmune Corp.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. Inimmune Corp.Startup |
Originator Org. Inimmune Corp.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date29 Mar 2024 |
Sponsor / Collaborator Inimmune Corp.Startup [+1] |
Start Date04 Jul 2023 |
Sponsor / Collaborator Inimmune Corp.Startup [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
INI-4001 ( TLR ) | Advanced Malignant Solid Neoplasm More | Phase 1 |
INI-2004 ( TLR4 ) | Rhinitis, Allergic, Seasonal More | Phase 1 |
MRSA Antibiotics(Inimmune) | MRSA - Methicillin resistant Staphylococcus aureus infection More | Preclinical |
Pseudomonas aeruginosa vaccine | Pseudomonas aeruginosa infection More | Preclinical |
INI-2002 | Pseudomonas Infections More | Discontinued |